Sheryl Kaboud
Family · Las Vegas, NVNPI 1619657996
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $713, more than ten times the $58 reported in 2023.
Across 49 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$211
- AbbVie$194
- Otsuka America Pharmaceutical, Inc.$125
- UCB, Inc.$122
- Alnylam Pharmaceuticals Inc.$64
- Amgen$48
- plus $448 from 17 others
What the payments were for
- Food & beverage$1,212100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 5 | $211 |
| AbbVie | 10 | $194 |
| Otsuka America Pharmaceutical, Inc. | 2 | $125 |
| UCB, Inc. | 5 | $122 |
| Alnylam Pharmaceuticals Inc. | 2 | $64 |
| Amgen | 2 | $48 |
| Astellas Pharma US Inc | 3 | $42 |
| Genentech USA, Inc. | 2 | $41 |
| Intra-sana Laboratories | 2 | $41 |
| AstraZeneca | 2 | $39 |
| Argenx US, Inc. | 2 | $39 |
| Tersera Therapeutics LLC | 1 | $30 |
| Novartis | 1 | $28 |
| Edwards Lifesciences | 1 | $21 |
| Grifols USA, LLC | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Braeburn Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,212 in reported general payments places this provider in the 70th percentile of 1,501 family providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $534 |
| Liothyronine Sodium | 13 | $362 |
| Atorvastatin Calcium | 22 | $198 |
| Levothyroxine Sodium | 33 | $172 |
| Rosuvastatin Calcium | 13 | $166 |
| Omeprazole | 11 | $164 |
| Zolpidem Tartrate | 17 | $101 |
| Tamsulosin Hcl | 15 | $96 |
| Alprazolam | 17 | $90 |
| Famotidine | 11 | $85 |
| Trazodone Hcl | 16 | $71 |
| Metoprolol Tartrate | 13 | $24 |
| Lisinopril | 13 | $20 |
Paid to pharmacies, not to this prescriber.
Other family in Las Vegas
- Hollie TylerLas Vegas$118K
- John PhoenixLas Vegas$107K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
- Erin WilkinsonLas Vegas$43K
- Anna Melisa Lopez-SanglayLas Vegas$42K
- Kelly PapeshLas Vegas$28K
- Bernard BlanksLas Vegas$26K
- Hillary DursteinLas Vegas$21K
- Victoria HughesLas Vegas$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.